Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytet

Details Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytet Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytet

1995-06-07

1997-08-12

Raymond, Richard L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514474, 549315, 549316, A61K 31365, C07D30762

Patent

active

056566620

ABSTRACT:
The present invention relates to a method for synthesis of optically pure 4-alkenyl or 4-alkanyl-2-hydroxytetronic acids from an optically pure aldehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase, thus making them useful in the treatment of coronary artery diseases, especially atherosclerosis, and additionally, as inhibitors of various inflammatory cytokines, making them useful in the treatment of both acute and chronic inflammation, as well in the treatment of cachexia, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis. The invention further relates to pharmaceutical compositions of the instant compounds.

REFERENCES:
patent: 5008405 (1991-04-01), Hatanaka et al.
patent: 5095126 (1992-03-01), Witiak et al.
patent: 5298526 (1994-03-01), Witiak et al.
patent: 5399721 (1995-03-01), Hopper
patent: 5504107 (1996-04-01), Mantri et al.
Haynes et al., "Tetronic Acids" Chem. Soc.: Quart. Rev., 1960, 292-315.
Ireland and Thompson, "An approach to the total synthesis of chlorothrieolide: the synthesis of the top half" J. Org. Chem., 1979, 44:3041-3052.
Kamanna et al., "Serum lipoprotein and apoprotein concentrations in 4-(4-chlorophenyl)-2-hydroxytetronic acid and clofibrate-treated cholesterol and cholic acid-fed rats" Lipids, 1989, 24:25-32.
Schank, "Reductones," Synthesis, 1972, 176-190.
Triozzi et al., "Aci-reductones enhance interleukin-2-induced lymphocytic cytotoxicity" Int. J. Immunopharmac., 1993, 15:47-54.
Witiak et al., "4-substituted-2-hydroxytetronic acid aci-reducones improve lymphokin-activated killer cell activity in vitro" Proc. Am. Assoc. Canc. Res., 1993, Florida, (#2665).
Witiak et al., "Chemical Approaches to the treatment of artherosclerosis" in Trends in Medicinal Chemistry, Blackwell Scientific Publications: Oxford, 1990, pp. 243-256.
Witiak et al., "Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids" J. Org. Chem., 1990, 55:1112-1114.
Witiak et al., "Medicinal chemistry aspects of antilipidemic drugs: acireductone antilipidemic and antiaggregatory agents" Actual Chem. Ther., 1988, 15:41-62.
Witiak et al., "Synthetic aci-reductones: 3,4-dihydroxy-2H-1-benzopyran-2-ones and their trans-4a,5,6,7,8,8a-hesahydro diastereomers" J. Med. Chem., 1988, 31:1437-1445.
Witiak and Tehim, "Synthetic approaches to 4-spiro-2-hydroxytetronic acids" J. Org. Chem., 1987, 52:2324-2327.
Witiak et al., "Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues and their relationship to clofibric acid" J. Med. Chem., 1986, 29:2170-2174.
Witiak et al., "Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3 dihydrobenzofuran analogue" J. Med. Chem., 1982, 25:90-93.

Affiliated with

Also associated with

Rating

Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytet does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytet, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytet will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-161059